Oncology · NK/T-Cell LymphomaTrial Updateclinicalmid-term

Tislelizumab and Zeprumetostat Show Promise in NK/T-Cell Lymphoma Phase Ib/II Trial

The ongoing phase Ib/II trial of tislelizumab and zeprumetostat represents a significant development in the treatment of relapsed or refractory NK/T-cell lymphoma. Positive trial outcomes could reshape treatment guidelines and enhance competitive positioning in this therapeutic area.

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/19/2026, 12:30:36 PM

Assessment confidence: 53% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

Strategic Assessment

Portfolio and strategy teams should monitor the trial's progress and results, as positive outcomes could influence treatment guidelines and market dynamics. The strongest clinical anchor is Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma (ClinicalTrials.gov), entity match (tislelizumab); patient population match (refractory). In Oncology · NK/T-Cell Lymphoma, 0 regulatory and 5 competitive items passed relevance filtering for tislelizumab.

Competitive Pressure

The most relevant competitive pressure comes from Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) (Merck) — sponsor/company relevance (merck). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study.

Regulatory Outlook

Regulatory risk is concentrated around The trial's outcomes may influence future regulatory approvals and labeling for both tislelizumab and zeprumetostat, depending on the efficacy demonstrated in the study..

Key Risks

Elevated medium regulatory exposure for tislelizumab could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.
Signal severity is high — leadership review is warranted.

Key Opportunities

Successful trial results could lead to increased market share for the combination therapy, particularly among patients who have exhausted other treatment options, potentially impacting revenue streams.
Upside for tislelizumab may improve if Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
Upside for tislelizumab may improve if Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o (ClinicalTrials.gov) delivers favorable follow-through.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC).
Upside for tislelizumab may improve if Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review. (PubMed) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Key milestones include the determination of the recommended phase II dose and the results of the objective response rate at week 12.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

No evidence in this category.

Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
ClinicalTrials.govhigh relevance
Entity match (tislelizumab); Patient population match (refractory)
FDA document
View source
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Investigation of Vitamin D and Menstrual Cycles Trial, the inVitD Trial: A Phase II Clinical Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Phase III Trial of Early Treatment in High-Risk CLL/SLL Shows Promise
Humanexa Signalsmedium relevance
Moderate corpus alignment
Sintilimab and Ipilimumab Show Promise in First-line Therapy for Advanced Biliary Tract Cancers
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase II Trial of ILDR Plus Immunochemotherapy in Borderline Resectable Esophageal Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

Lactylation and liquid-liquid phase separation related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma patients.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

tislelizumab

Commercial impact

medium

Successful trial results could lead to increased market share for the combination therapy, particularly among patients who have exhausted other treatment options, potentially impacting revenue streams.

Regulatory impact

medium

The trial's outcomes may influence future regulatory approvals and labeling for both tislelizumab and zeprumetostat, depending on the efficacy demonstrated in the study.

What to watch

Key milestones include the determination of the recommended phase II dose and the results of the objective response rate at week 12.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.